| Statement |
1.Date of the shareholders' meeting resolution:2025/06/20
2.Name and title of the managerial officer with permission
to engage in competitive conduct:
Director:Chang Ming-Cheng
Director:Fu Jo-Hsuan
Director:Excelsior Medical Co., Ltd.Representative:Chou Cheng-Hsiao
Independent director:Liao Yi-Hsing
Independent director:Tseng Tsui-Chen
Independent director: Lin Feng-Jyh
3.Items of competitive conduct in which the officer is
permitted to engage:Invest or operate other companies with the
same or similar business scope as our company and serving as a director.
4.Period of permission to engage in the competitive conduct:
Within period of serving as director and independent director of the Company.
5.Circumstances of the resolution (please describe the
results of voting in accordance with Article 209 of the
Company Act):
This proposal has been approved as originally proposed by the Board of
Directors, with the attendance of shareholders representing more than
half of the total issued shares and with the consent of more than
two-thirds of the voting rights of the attending shareholders.
6.If the permitted competitive conduct belongs to the
operator of a mainland China enterprise, the name and
title of the directors (if it is not the operator of
a mainland China enterprise, please enter “N/A” below):
Director:Excelsior Medical Co., Ltd.Representative:Chou Cheng-Hsiao
7.Company name of the mainland China enterprise and the
officer’s position in the enterprise:
Director:Excelsior Medical Co., Ltd.Representative:Chou Cheng-Hsiao,
Supervisor of SinoExcelsior Investment Inc.
8.Address of the mainland China enterprise:
Room 301-2, Building 1, No. 1089 Kangning Road, Shanghai, China
9.Operations of the mainland China enterprise:
SinoExcelsior Investment Incorporation:Corporate management consulting;
Sales of Class I medical devices;Import and export of goods;
Import and export of technology;Internet sales (excluding sales of
products requiring licenses);Sales agency;Health consulting services
(excluding diagnostic services);Information consulting services
(excluding licensed information consulting services);
Technical services,Technical development,Technical consulting,
Technical exchange,Technology transfer,Technology promotion;
Marketing planning;Wholesale of cosmetics.
10.Impact on the company’s finance and business:None.
11.If the directors have invested in the mainland China
enterprise, the monetary amount of the investment and
their shareholding ratio:None.
12.Any other matters that need to be specified:None.
|
